Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vericiguat · Verquvo, MK-1242

Small molecule · Activator of soluble guanylate cyclase (GUCY1A1) · developed by Msd

Approved FDA, Jan 2021
MRK Developer

What is Vericiguat?

Vericiguat is an orally bioavailable stimulator of soluble guanylate cyclase (sGC) that acts synergistically with nitric oxide to increase intracellular cGMP, leading to smooth muscle relaxation and vasodilation. It is studied in heart failure and left ventricular systolic dysfunction.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Verquvo, MK-1242, BAY-1021189
Drug type
Small molecule
Targets
soluble guanylate cyclase (GUCY1A1)
Mechanism
Activator of soluble guanylate cyclase (GUCY1A1)
Pathways
nitric oxide-cGMP signaling, smooth muscle relaxation and vasodilation
Therapy area
Cardiovascular
Developer
Msd (MRK)
FDA status
Approved as Verquvo (January 19, 2021), NDA214377 · FDA label
UNII
LV66ADM269

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 21, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Heart FailureLeft Ventricular Systolic Dysfunction

More from Msd

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Vericiguat

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.